An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Recruiting
Observational Study
Crohn's Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 15 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 240 (estimated)
- Sponsor
- AbbVie · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world. Adverse events and change in disease activity will be assessed.
Upadacitinib is a drug approved for the treatment of CD. All study participants will receive upadacitinib as prescr…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosed with moderately to severely active Crohn's disease (CD).
* Has been prescribed upadacitinib for CD as per most current local approved label after its approval for CD in Japan.
* Within 14 days from the commencement of upadacitinib induction treatment for CD at the pa…
Contacts
AbbVie GK Clinical Trial Registration Desk
+81-3-4577-1111
abbvie_jpn_info_clingov@abbvie.com
CONTACT